Silexion Therapeutics Corp SLXN
At closeNov 4, 2026, 6:19 PM EST
After hours · Nov 4, 6:19 PM ET
- YTD
- -99.20%
- 1 year
- -99.49%
- Market cap
- 2.34M
- EPS (ttm)
- -27.79
- Shares out
- 1.60M
- Forward P/E
- -3.95
- YTD return
- -99.20%
- 1-year return
- -99.49%
- Volume
- 126.23K
- Avg volume
- 10.26M
- Open
- 0.1534
- Previous close
- 0.1526
- Day's range
- 0.1512 – 0.1577
- 52-week range
- 0.14 – 32.38
- Beta
- -0.11
- Analysts
- Buy
- Price target
- 9.00 (+5763.2%)
2Y -37.6438 (-99.59%)
Key statistics
- Enterprise value
- 16.46M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -305.63K
- Total cash
- 2.78M
- Total debt
- 144.00K
- Return on equity
- -116.66%
- Short % of float
- 3.08%
- 50-day average
- 1.12
- 200-day average
- 6.82
Analyst view
Consensus: buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -18.27 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | Maxim Group | init | — | Buy |
About Silexion Therapeutics Corp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- silexion.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Friday's After-Market Session - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic Cancer 
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer 
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - 12 Health Care Stocks Moving In Tuesday's Intraday Session
Silexion Therapeutics To Raise $837K Via Exercise Of ~3.217M Series E Warrants At $0.2603/Share - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Silexion Therapeutics Announces Exercise of Warrants
Your note
Sign in to keep a note on SLXN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wildcat Capital Management, LLC | 0.79% | 113,428 | 286.97K | Sep 29, 2024 |
| HRT Financial LP | 0.07% | 9,997 | 25.29K | Sep 29, 2024 |
| Virtu Financial LLC | 0.02% | 2,962 | 7.49K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.01% | 1,680 | 4.25K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 1,673 | 4.23K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 587 | 1.49K | Oct 30, 2024 |